Oridonin-loaded and GPC1-targeted gold nanoparticles for multimodal imaging and therapy in pancreatic cancer

Wenli Qiu,1 Rong Chen,2 Xiao Chen,3 Huifeng Zhang,1 Lina Song,3 Wenjing Cui,3 Jingjing Zhang,1 Dandan Ye,1 Yifen Zhang,4 Zhongqiu Wang3 1The First Clinical Medical School, Nanjing University of Chinese Medicine, Nanjing, People’s Republic of China; 2Department of Diagnostic Radiology and...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Qiu W, Chen R, Chen X, Zhang H, Song L, Cui W, Zhang J, Ye D, Zhang Y, Wang Z
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2018
Materias:
ORI
Acceso en línea:https://doaj.org/article/7fb3e23da294446199a3fef41cf74b5f
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:7fb3e23da294446199a3fef41cf74b5f
record_format dspace
spelling oai:doaj.org-article:7fb3e23da294446199a3fef41cf74b5f2021-12-02T04:50:29ZOridonin-loaded and GPC1-targeted gold nanoparticles for multimodal imaging and therapy in pancreatic cancer1178-2013https://doaj.org/article/7fb3e23da294446199a3fef41cf74b5f2018-10-01T00:00:00Zhttps://www.dovepress.com/oridonin-loaded-and-gpc1-targeted-gold-nanoparticles-for-multimodal-im-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Wenli Qiu,1 Rong Chen,2 Xiao Chen,3 Huifeng Zhang,1 Lina Song,3 Wenjing Cui,3 Jingjing Zhang,1 Dandan Ye,1 Yifen Zhang,4 Zhongqiu Wang3 1The First Clinical Medical School, Nanjing University of Chinese Medicine, Nanjing, People’s Republic of China; 2Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, MD, USA; 3Department of Radiology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, People’s Republic of China; 4Department of Pathology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, People’s Republic of China Purpose: Early diagnosis and therapy are critical to improve the prognosis of patients with pancreatic cancer. However, conventional imaging does not significantly increase the capability to detect early stage disease. In this study, we developed a multifunctional theranostic nanoplatform for accurate diagnosis and effective treatment of pancreatic cancer.Methods: We developed a theranostic nanoparticle (NP) based on gold nanocages (AuNCs) modified with hyaluronic acid (HA) and conjugated with anti-Glypican-1 (anti-GPC1) antibody, oridonin (ORI), gadolinium (Gd), and Cy7 dye. We assessed the characteristics of GPC1-Gd-ORI@HAuNCs-Cy7 NPs (ORI-GPC1-NPs) including morphology, hydrodynamic size, stability, and surface chemicals. We measured the drug loading and release efficiency in vitro. Near-infrared fluorescence (NIRF)/magnetic resonance imaging (MRI) and therapeutic capabilities were tested in vitro and in vivo.Results: ORI-GPC1-NPs demonstrated long-time stability and fluorescent/MRI properties. Bio-transmission electron microscopy (bio-TEM) imaging showed that ORI-GPC1-NPs were endocytosed into PANC-1 and BXPC-3 (overexpression GPC1) but not in 293 T cells (GPC1-negative). Compared with ORI and ORI-NPs, ORI-GPC1-NPs significantly inhibited the viability and enhanced the apoptosis of pancreatic cancer cells in vitro. Moreover, blood tests suggested that ORI-GPC1-NPs showed negligible toxicity. In vivo studies showed that ORI-GPC1-NPs enabled multimodal imaging and targeted therapy in pancreatic tumor xenografted mice.Conclusion: ORI-GPC1-NP is a promising theranostic platform for the simultaneous diagnosis and effective treatment of pancreatic cancer. Keywords: pancreatic cancer, GPC1, ORI, theranosticQiu WChen RChen XZhang HSong LCui WZhang JYe DZhang YWang ZDove Medical Pressarticlepancreatic cancerGPC1ORItheranosticMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 13, Pp 6809-6827 (2018)
institution DOAJ
collection DOAJ
language EN
topic pancreatic cancer
GPC1
ORI
theranostic
Medicine (General)
R5-920
spellingShingle pancreatic cancer
GPC1
ORI
theranostic
Medicine (General)
R5-920
Qiu W
Chen R
Chen X
Zhang H
Song L
Cui W
Zhang J
Ye D
Zhang Y
Wang Z
Oridonin-loaded and GPC1-targeted gold nanoparticles for multimodal imaging and therapy in pancreatic cancer
description Wenli Qiu,1 Rong Chen,2 Xiao Chen,3 Huifeng Zhang,1 Lina Song,3 Wenjing Cui,3 Jingjing Zhang,1 Dandan Ye,1 Yifen Zhang,4 Zhongqiu Wang3 1The First Clinical Medical School, Nanjing University of Chinese Medicine, Nanjing, People’s Republic of China; 2Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, MD, USA; 3Department of Radiology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, People’s Republic of China; 4Department of Pathology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, People’s Republic of China Purpose: Early diagnosis and therapy are critical to improve the prognosis of patients with pancreatic cancer. However, conventional imaging does not significantly increase the capability to detect early stage disease. In this study, we developed a multifunctional theranostic nanoplatform for accurate diagnosis and effective treatment of pancreatic cancer.Methods: We developed a theranostic nanoparticle (NP) based on gold nanocages (AuNCs) modified with hyaluronic acid (HA) and conjugated with anti-Glypican-1 (anti-GPC1) antibody, oridonin (ORI), gadolinium (Gd), and Cy7 dye. We assessed the characteristics of GPC1-Gd-ORI@HAuNCs-Cy7 NPs (ORI-GPC1-NPs) including morphology, hydrodynamic size, stability, and surface chemicals. We measured the drug loading and release efficiency in vitro. Near-infrared fluorescence (NIRF)/magnetic resonance imaging (MRI) and therapeutic capabilities were tested in vitro and in vivo.Results: ORI-GPC1-NPs demonstrated long-time stability and fluorescent/MRI properties. Bio-transmission electron microscopy (bio-TEM) imaging showed that ORI-GPC1-NPs were endocytosed into PANC-1 and BXPC-3 (overexpression GPC1) but not in 293 T cells (GPC1-negative). Compared with ORI and ORI-NPs, ORI-GPC1-NPs significantly inhibited the viability and enhanced the apoptosis of pancreatic cancer cells in vitro. Moreover, blood tests suggested that ORI-GPC1-NPs showed negligible toxicity. In vivo studies showed that ORI-GPC1-NPs enabled multimodal imaging and targeted therapy in pancreatic tumor xenografted mice.Conclusion: ORI-GPC1-NP is a promising theranostic platform for the simultaneous diagnosis and effective treatment of pancreatic cancer. Keywords: pancreatic cancer, GPC1, ORI, theranostic
format article
author Qiu W
Chen R
Chen X
Zhang H
Song L
Cui W
Zhang J
Ye D
Zhang Y
Wang Z
author_facet Qiu W
Chen R
Chen X
Zhang H
Song L
Cui W
Zhang J
Ye D
Zhang Y
Wang Z
author_sort Qiu W
title Oridonin-loaded and GPC1-targeted gold nanoparticles for multimodal imaging and therapy in pancreatic cancer
title_short Oridonin-loaded and GPC1-targeted gold nanoparticles for multimodal imaging and therapy in pancreatic cancer
title_full Oridonin-loaded and GPC1-targeted gold nanoparticles for multimodal imaging and therapy in pancreatic cancer
title_fullStr Oridonin-loaded and GPC1-targeted gold nanoparticles for multimodal imaging and therapy in pancreatic cancer
title_full_unstemmed Oridonin-loaded and GPC1-targeted gold nanoparticles for multimodal imaging and therapy in pancreatic cancer
title_sort oridonin-loaded and gpc1-targeted gold nanoparticles for multimodal imaging and therapy in pancreatic cancer
publisher Dove Medical Press
publishDate 2018
url https://doaj.org/article/7fb3e23da294446199a3fef41cf74b5f
work_keys_str_mv AT qiuw oridoninloadedandgpc1targetedgoldnanoparticlesformultimodalimagingandtherapyinpancreaticcancer
AT chenr oridoninloadedandgpc1targetedgoldnanoparticlesformultimodalimagingandtherapyinpancreaticcancer
AT chenx oridoninloadedandgpc1targetedgoldnanoparticlesformultimodalimagingandtherapyinpancreaticcancer
AT zhangh oridoninloadedandgpc1targetedgoldnanoparticlesformultimodalimagingandtherapyinpancreaticcancer
AT songl oridoninloadedandgpc1targetedgoldnanoparticlesformultimodalimagingandtherapyinpancreaticcancer
AT cuiw oridoninloadedandgpc1targetedgoldnanoparticlesformultimodalimagingandtherapyinpancreaticcancer
AT zhangj oridoninloadedandgpc1targetedgoldnanoparticlesformultimodalimagingandtherapyinpancreaticcancer
AT yed oridoninloadedandgpc1targetedgoldnanoparticlesformultimodalimagingandtherapyinpancreaticcancer
AT zhangy oridoninloadedandgpc1targetedgoldnanoparticlesformultimodalimagingandtherapyinpancreaticcancer
AT wangz oridoninloadedandgpc1targetedgoldnanoparticlesformultimodalimagingandtherapyinpancreaticcancer
_version_ 1718401015954276352